🔗 Share this article

While the US continues making unprecedented adjustments to its vaccine guidelines, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by questioning Covid vaccinations in the pandemic and has zeroed in on possible deaths after COVID-19 immunization in her short position at the FDA.

Planned Shifts to Childhood Vaccine Schedule

Agency leaders were set to announce major changes to the childhood immunization program in December, bringing the US with Denmark’s vaccine program, according to reports – a major change that would put the US at odds with much of the international standard with little proof for improved outcomes. This reveal has been pushed back until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to present at the event. She was just designated interim head of the FDA’s CDER, the fifth individual to run the center this year.

A Shift at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has often pushed for halting some childhood immunization guidelines in the US to become more in line with Denmark's approach, a society with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – usually the domain of Prasad, head of the FDA’s vaccine center – rather than medication approval.

Questions Over Qualifications

The appointee has no apparent experience in drug development, approval processes or management, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and CBER since March.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in drug approvals.”

Past directors of CBER would “grasp legal statutes and the science of medication creation”, said a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that previous people who ran the center have had.”

This division has an enormous workload at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the new drug program, but the off-patent medication office approves a multitude of generic medications. There is also a biologic copycat branch, OTC medication office and other areas, and each of these have to be managed,” Woodcock explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial administrative element to the job, which manages in excess of 5,000 staff members. “It’s a massive administrative position, if you do it right,” she said.

Official Statement and Controversial Programs

In response to concerns about Høeg’s qualifications and whether this assignment represents greater collaboration among agency officials on immunizations, a representative responded that the “inquiries are based on incorrect premises”.

“Her experience is consistent with the functions of her position,” the spokesperson explained, noting the months Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the agency head's new fast-track approval initiative, a disputed expedited drug-approval program that allegedly concerned her predecessors. “How are these drugs being picked for this fast-track system? Who is making the decisions?” Howard questioned. “There is a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards less stringent oversight of most medications, with the exception of vaccines.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if troubling, history, some experts observe. She authored a analysis using non-validated public submissions to assess the frequency of heart inflammation after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the current government featured revising regulations for new vaccines and halting “optional” immunizations, she said post-election on a online show. At the FDA, Høeg has allegedly proposed excluding teenage boys from receiving Covid vaccines.

“She’s an complete ideologue who begins with her beliefs and reverse-engineers to retrofit the evidence in a extremely disingenuous, untruthful manner,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|